News & Updates

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

In solid organ transplant recipients with moderate symptoms of SARS-CoV-2 infection, early administration of a 3-day remdesivir course appears to effectively prevent COVID-19-related hospitalization as well as the clinical worsening of those who are hospitalized, according to a study.

Short-term concurrent androgen deprivation therapy (ADT) results in markedly worse overall survival (OS) among intermediate-risk (IR) prostate cancer patients on dose-escalated intensity modulated radiation therapy (IMRT) with daily image-guided RT, reveals a study.

While mothers largely feel uncertain about the safety of breastfeeding during COVID-19, the pandemic did not seem to significantly discourage the practice, according to a study presented at the 2022 Annual Clinical & Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG 2022).

In patients with multiple myeloma (MM), a higher allostatic load (AL) seems to be an important predictor of worse overall survival (OS), a recent study has found.